NCT03840317

Randomized, Parallel-arm, Controlled Trial of Senl_1904A and Senl_1904B Autologous CAR-T Cell Injections in the Treatment of Relapsed and Refractory Acute B Lymphocytic Leukemia(r/r B-ALL)

Study Summary

This is an open, two arms, mask phase I clinical study to evaluate efficacy and safety of two different chimeric antigen receptor T cell immunotherapies (Senl\_1904A and Senl\_1904B) targeting cluster of differentiation antigen 19 (CD19) in the treatment of Acute lymphocytic Leukemia. A total of 20 patients are planned to be enrolled following up half a year.

Want to learn more about this trial?

Request More Info

Interventions

Autologous CD19-targeting CAR T cellsBIOLOGICAL
Autologous CD19-targeting CAR T cells

Study Locations

FacilityCityStateCountry
Hebei Yanda Ludaopei HospitalLangfangHebeiChina

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026